Innovative solutions that meet the most stringent quality regulations and are compatible with food industry standards ...

Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

At June 30, 2025, the Company's cash and cash equivalents were $695.6 million, after payment of $276.4 million for the Evergreen Theragnostics, Inc. (“Evergreen”) acquisition, which closed early in ...

Neurorehabilitation: Transforming lives via interdisciplinary approach for atypical Parkinsonism: Dr. Vignesh Srinivasan & Dr. Poovarasan Wednesday, August 6, 2025, 08:00 Hrs [IST ...

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update. Three active immunotherapies for precision prevention of neurodegeneration progressing thr ...

Traditionally, the diagnosis of Alzheimer’s disease has been based on informant interviews and clinical assessments of memory, cognition, behaviour, and mood. To increase diagnostic confidence, ...

A key next step is using tau PET imaging to explore how toxic tau proteins accumulate in the brain and disrupt memory ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Laboratory tests using blood-based biomarkers (BBB) to identify the presence or risk of Alzheimer's disease (AD) in the brain ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

The FDA cleared the use of the first approved blood test that can help diagnose Alzheimer’s disease. Learn more from U of U ...